Table 2.

The correlations between patient characteristics and IHC expressions.

		Age (mean = 55.7)			FIGO stage			Residual tumour			Recurrence			Death
		<56	≥56	p value	I + II	III + IV	p value	Yes	No	p value	Yes	No	p value	Yes	No	p value
ALL		50	56		87	19		90	16		32	74		23	83
ARID1A	Positive	27	27	0.345	43	11	0.340	44	10	0.233	15	39	0.367	10	44	0.283
	Loss	23	29		44	8		46	6		17	35		13	39
HDAC6N	High	26	33	0.301	49	10	0.482	49	10	0.376	20	39	0.237	17	42	0.038
	Low	24	23		38	9		41	6		12	35		6	41
HDAC6C	High	8	12	0.322	16	4	0.504	17	3	0.647	8	12	0.212	6	14	0.237
	Low	42	44		71	15		73	13		24	62		17	69
HIF-1α	High	29	31	0.469	49	11	0.554	50	10	0.408	22	38	0.073	17	43	0.047
	Low	21	25		38	8		40	6		10	36		6	40
PD-L1	High	3	4	0.564	5	2	0.367	5	2	0.285	4	3	0.121	4	3	0.038
	Low	47	52		82	17		85	14		28	71		19	80
CD44	High	12	12	0.466	18	6	0.229	18	6	0.114	12	12	0.018	9	15	0.036
	Low	38	44		69	13		72	10		20	62		14	68

HDAC6N, histone deacetylase 6 nuclear expression; HDAC6C, HDAC6 cytoplasmic expression; HIF-1α, hypoxia inducible factor-1α; PD-L1, programmed death-1 ligand. p value < 0.05 is shown in bold.